Evidence map›Paper›PMID 35101137›Full record

ArticleEuropean journal of medical research2022

Gene-gene interaction of AhRwith and within the Wntcascade affects susceptibility to lung cancer.

Albert Rosenberger, Nils Muttray, Rayjean J Hung, David C Christiani, Neil E Caporaso, Geoffrey Liu, Stig E Bojesen, Loic Le Marchand, Demetrios Albanes, Melinda C Aldrich and 31 more

Open access · goldAbstract read
In one paragraph

Article in European journal of medical research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 54% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. [FNDC1 is highly expressed in lung adenocarcinoma and closely related with poor prognosis].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

41 authors at 20 institutions in 12 countries.

Albert RosenbergerDepartment of Genetic Epidemiology, University Medical Center, Georg-August-University Göttingen, Göttingen, Germany. arosenb@gwdg.de.ORCID http://orcid.org/0000-0001-7848-1332
Nils MuttrayDepartment of Genetic Epidemiology, University Medical Center, Georg-August-University Göttingen, Göttingen, Germany.
Rayjean J HungLunenfeld-Tanenbaum Research Institute, Sinai Health System, University of Toronto, Toronto, ON, Canada.
David C ChristianiDepartment of Environmental Health, Harvard T.H. Chan School of Public Health and Massachusetts General Hospital/Harvard Medical School, Boston, MA, USA.
Neil E CaporasoDivision of Cancer Epidemiology and Genetics, National Cancer Institute, US National Institutes of Health, Bethesda, MD, USA.
Geoffrey LiuMedical Oncology and Medical Biophysics, Princess Margaret Cancer Centre, Toronto, ON, Canada.
Stig E BojesenDepartment of Clinical Biochemistry, Herlev and Gentofte Hospital, Copenhagen University Hospital, Copenhagen, Denmark.
Loic Le MarchandEpidemiology Program, University of Hawaii Cancer Center, Honolulu, HI, USA.
Demetrios AlbanesDivision of Cancer Epidemiology and Genetics, National Cancer Institute, US National Institutes of Health, Bethesda, MD, USA.
Melinda C AldrichDepartment of Thoracic Surgery, Division of Epidemiology, Vanderbilt University Medical Center, Nashville, TN, USA.
Adonina TardonFaculty of Medicine, University of Oviedo, ISPA and CIBERESP, Oviedo, Spain.
Guillermo Fernández-TardónFaculty of Medicine, University of Oviedo, ISPA and CIBERESP, Oviedo, Spain.
Gad RennertClalit National Cancer Control Center at Carmel Medical Center and Technion Faculty of Medicine, Haifa, Israel.
John K FieldDepartment of Molecular and Clinical Cancer Medicine, Roy Castle Lung Cancer Research Programme, The University of Liverpool, Liverpool, UK.
Michael P A DaviesDepartment of Molecular and Clinical Cancer Medicine, Roy Castle Lung Cancer Research Programme, The University of Liverpool, Liverpool, UK.
Triantafillos LiloglouDepartment of Molecular and Clinical Cancer Medicine, Roy Castle Lung Cancer Research Programme, The University of Liverpool, Liverpool, UK.
Lambertus A KiemeneyDepartments of Health Evidence and Urology, Radboud University Medical Center, Nijmegen, The Netherlands.
Philip LazarusDepartment of Pharmaceutical Sciences, College of Pharmacy, Washington State University, Spokane, WA, USA.
Bernadette WendelDepartment of Genetic Epidemiology, University Medical Center, Georg-August-University Göttingen, Göttingen, Germany.
Aage HaugenNational Institute of Occupational Health, Oslo, Norway.
Shanbeh ZienolddinyNational Institute of Occupational Health, Oslo, Norway.
Stephen LamBritish Columbia Cancer Agency, Vancouver, BC, Canada.
Matthew B SchabathDepartment of Cancer Epidemiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Angeline S AndrewDepartment of Epidemiology, Geisel School of Medicine, Hanover, NH, USA.
Eric J DuellUnit of Biomarkers and Susceptibility, Oncology Data Analytics Program, Catalan Institute of Oncology (ICO), Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain.
Susanne M ArnoldMarkey Cancer Center, University of Kentucky, Lexington, KY, USA.
Gary E GoodmanSwedish Medical Group, Seattle, WA, USA.
Chu ChenProgram in Epidemiology, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Jennifer A DohertyDepartment of Population Health Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
Fiona TaylorDepartment of Oncology and Metabolism, University of Sheffield, Sheffield, UK.
Angela CoxDepartment of Oncology and Metabolism, University of Sheffield, Sheffield, UK.
Penella J WollDepartment of Oncology and Metabolism, University of Sheffield, Sheffield, UK.
Angela RischUniversity of Salzburg and Cancer Cluster Salzburg, Salzburg, Austria.
Thomas R MuleyMember of the German Center for Lung Research (DZL), Translational Lung Research Center (TLRC) Heidelberg, Heidelberg, Germany.
Mikael JohanssonDepartment of Radiation Sciences, Umeå University, Umeå, Sweden.
Paul BrennanInternational Agency for Research on Cancer, World Health Organization, Lyon, France.
Maria Teresa LandiDivision of Cancer Epidemiology and Genetics, National Cancer Institute, US National Institutes of Health, Bethesda, MD, USA.
Sanjay S SheteDepartment of Biostatistics, Division of Basic Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Christopher I AmosDan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA.
Heike BickeböllerDepartment of Genetic Epidemiology, University Medical Center, Georg-August-University Göttingen, Göttingen, Germany.
INTEGRAL-ILCCO Consortium
National Institutes of Health · USUniversity of Göttingen · DEUniversity of Liverpool · GBUniversity of Sheffield · GBNational Institute of Occupational Health · NOUniversidad de Oviedo · ESUniversity of Toronto · CABaylor College of Medicine · USBC Cancer Agency · CACarmel Medical Center · ILCentre international de recherche sur le cancer · FRDartmouth College · USFred Hutch Cancer Center · USHarvard University · USHeidelberg University · DEInstitut d'Investigació Biomédica de Bellvitge · ESMoffitt Cancer Center · USRadboud University Nijmegen · NLSwedish Medical Center · USThe University of Texas MD Anderson Cancer Center · US

Funding

TRANSLATIONAL RESEARCHP30CA076292 · NCI · UNIVERSITY OF SOUTH FLORIDA · PI John L. Cleveland · 1998 to 2026
$93.5M
Translating Molecular and Clinical Data to Population Lung Cancer Risk AssessmentU19CA203654 · NCI · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI Christopher I. Amos · 2017 to 2026
$23.7M
THE CAROTENE AND RETINOL EFFICACY TRIAL (CARET)U01CA063673 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI GOODMAN, GARY E · 1994 to 2006
$13.0M
Statistical Methods for Analysis of Massive Genetic and Genomic Data in Cancer ResearchR35CA197449 · NCI · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI XIHONG LIN · 2015 to 2026
$10.9M
Infrastructure Support and Pilot Tissue Collection for the CARET BiorepositoryU01CA167462 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI NEUHOUSER, MARIAN L · 2018 to 2022
$2.9M
INFRASRUCTURE SUPPORT AND DATA ENHANCEMENTS FOR THE CARET BIOREPOSITORYUM1CA167462 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI GOODMAN, GARY E · 2013 to 2017
$2.8M
Telomeres and lung cancer incidence and survivalR01CA151989 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI DOHERTY, JENNIFER A. · 2011 to 2014
$2.4M
MOLECULAR EPIDEMIOLOGY OF LUNG CANCERR01CA111703 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI CHEN, CHU · 2006 to 2010
$2.2M
NCI NIH HHS P30 CA076292NCI NIH HHS R01 CA111703NCI NIH HHS R01 CA151989NCI NIH HHS R35 CA197449NCI NIH HHS U01 CA063673NCI NIH HHS U01 CA167462NCI NIH HHS U19 CA203654NCI NIH HHS UM1 CA167462World Health Organization 001
6 · The paper itself

Abstract

backgroundAberrant Wnt signalling, regulating cell development and stemness, influences the development of many cancer types. The Aryl hydrocarbon receptor (AhR) mediates tumorigenesis of environmental pollutants. Complex interaction patterns of genes assigned to AhR/Wnt-signalling were recently associated with lung cancer susceptibility.

aimTo assess the association and predictive ability of AhR/Wnt-genes with lung cancer in cases and controls of European descent.

methodsOdds ratios (OR) were estimated for genomic variants assigned to the Wnt agonist and the antagonistic genes DKK2, DKK3, DKK4, FRZB, SFRP4 and Axin2. Logistic regression models with variable selection were trained, validated and tested to predict lung cancer, at which other previously identified SNPs that have been robustly associated with lung cancer risk could also enter the model. Furthermore, decision trees were created to investigate variant × variant interaction. All analyses were performed for overall lung cancer and for subgroups.

resultsNo genome-wide significant association of AhR/Wnt-genes with overall lung cancer was observed, but within the subgroups of ever smokers (e.g., maker rs2722278 SFRP4; OR  = 1.20; 95% CI 1.13-1.27; p  = 5.6 × 10

conclusionsThe role of variants belonging to Wnt/AhR-pathways in lung cancer susceptibility may be underrated in main-effects association analysis. Complex interaction patterns in individuals of European descent have moderate predictive capacity for lung cancer or subgroups thereof, especially in never smokers.

Indexed as

Gene Expression Regulation, NeoplasticGenetic Predisposition to DiseaseBasic Helix-Loop-Helix ProteinsFemaleGenome-Wide Association StudyGenotypeHumansLung NeoplasmsMaleMiddle AgedReceptors, Aryl HydrocarbonRNA, NeoplasmWnt Signaling PathwayAHR protein, humanBasic Helix-Loop-Helix ProteinsReceptors, Aryl HydrocarbonRNA, NeoplasmAssociationDecision treesGene–gene integrationNever smokerPolygenic risk scorePredictionSmall cell lung cancerSusceptibility

Identifiers

PMID35101137
PMCPMC8805279
OpenAlexW4220777540

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.